Dapagliflozin
CAS No. : 461432-26-8
(Synonyms: BMS-512148)
| Size | Price | Stock |
|---|---|---|
| 5mg | $50 | In-stock |
| 10mg | $70 | In-stock |
| 25mg | $94 | In-stock |
| 50mg | $110 | In-stock |
| 100mg | $140 | In-stock |
| 250mg | $252 | In-stock |
| 500mg | $420 | In-stock |
| 1 g | Get quote | |
| 5 g | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-10450 |
| M.Wt: | 408.87 |
| Formula: | C21H25ClO6 |
| Purity: | >98 % |
| Solubility: | DMSO : ≥ 100 mg/mL;H2O : 50 mg/mL (ultrasonic) |
Dapagliflozin (BMS-512148), a new type of drug used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine[1]. Dapagliflozin induces HIF1 expression and attenuates renal IR injury[2]. IC50 & Target: SGLT2[1] In Vitro: Dapagliflozin (0-10 μM；24 hours) significantly increases the cell survival in hypoxic HK2 cell in a dose-dependent manner[2].Dapagliflozin (0-10 μM；2 hours) increases the HIF1 expression, increases AMPK and EKR phosphorylation in hypoxic HK2 cells, but shows no effect on the phosphorylation of AMPK and ERK in normoxic HK2 cells[2].. In Vivo: Dapagliflozin (oral administration; 10 mg/kg) causes a marked increase in urinary glucose in SGLT2i-mice, suppresses BAT thermogenesis by reducing sympathetic nerve activity and enhances hepatic gluconeogenesis and glycogenolysis[3].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Dapagliflozin
- Cat. No.:
- HY-10450
- Quantity:
Your information is safe with us.